

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOSTIME

Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

**GRANT OF AWARDED SHARES PURSUANT TO
2011 SHARE AWARD SCHEME**

On 23 December 2016, the Board (including all independent non-executive Directors), based on the recommendation by the remuneration committee of the Board of the Company, resolved to grant a total of 328,048 Awarded Shares to 7 employees who are Eligible Persons pursuant to the 2011 Scheme, including (i) Mr. Luo Fei, who is the chief executive officer, an executive Director and the chairman of the Company and (ii) 6 Participants, who are directors of subsidiaries of the Company.

Reference is made to the announcements of Biostime International Holdings Limited (the “**Company**”) dated 28 November 2011 and 30 March 2012 (the “**Announcements**”) relating to the adoption of a share award scheme (the “**2011 Scheme**”) of the Company and amendment to the 2011 Scheme. Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings ascribed to them in the Announcements.

On 23 December 2016, the Board (including all independent non-executive Directors), based on the recommendation by the remuneration committee of the Board of the Company, resolved to grant a total of 328,048 shares of the Company (the “**Awarded Shares**”) to 7 employees who are Eligible Persons pursuant to the 2011 Scheme. The grantees of the Awarded Shares include (i) Mr. Luo Fei, who is the chief executive officer, an executive Director and the chairman of the Company; and (ii) 6 Participants, who are directors of subsidiaries of the Company and are not connected persons of the Company at the Company’s level. Details of the grant are as follows:

Name of Participants	No. of Awarded Shares	Vesting Date
Mr. Luo Fei	77,828	1 April 2018
6 Participants who are directors of subsidiaries of the Company and are not connected persons of the Company at the Company's level	7,713	1 April 2017
	242,507	1 April 2018

The closing price of the Shares of the Company on the date of grant of the Awarded Shares is HK\$23.30 per Share. Pursuant to the 2011 Scheme, the grant of the said Awarded Shares was made by the Board by way of allocation of shares previously awarded under the 2011 Scheme which did not vest and were lapsed and which are currently held by the Trustee. Pursuant to the rules of the 2011 Scheme, the Awarded Shares have been granted to the grantees of such Awarded Shares for no consideration.

As Mr. Luo Fei is the chief executive officer and an executive Director of the Company and 6 Participants are directors of subsidiaries of the Company, they are connected persons of the Company. The grant of Awarded Shares to Mr. Luo Fei has been approved by the independent non-executive Directors of the Company as required under the 2011 Scheme. Mr. Luo Fei has abstained from voting so far as the resolution for the approval of the grant of Awarded Shares to him was concerned.

The grant of Awarded Shares to Mr. Luo Fei forms part of his remuneration under his service contract entered into with the Company and therefore is exempt from the reporting, announcement and independent shareholders' approval requirements pursuant to Rules 14A.73(6) and 14A.95 of the Listing Rules. The grant of Awarded Shares to the 6 directors of subsidiaries of the Company is exempt from the reporting, announcement and independent shareholders' approval requirements pursuant to Rule 14A.76(1)(b) of the Listing Rules as all the relevant percentage ratios under the Listing Rules for the grant of Awarded Shares are less than 1% and they are connected persons of the Company at the subsidiary level.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 23 December 2016

As at the date of this announcement, the executive Directors are Mr. Luo Fei and Mr. Radek Sali; the non-executive Directors are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.